Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
Stephen Jun Fei Chong(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Liam Hackett(Dana-Farber Cancer Institute), Jolin Xiao Hui Lai(National University of Singapore), John N. Allan(Cornell University), Olga Dashevsky(Broad Institute), Romain Guièze(Broad Institute), Ruben D. Carrasco(Brigham and Women's Hospital), Mary C. Collins(Dana-Farber Cancer Institute), Rin Mizuno(Harvard University), Boon Cher Goh(National University of Singapore), Jean‐Philippe Coppé(University of California, San Francisco), Catherine J. Wu(Dana-Farber Cancer Institute), Mehdi Bouhaddou(QB3), Fen Zhu(Dana-Farber Cancer Institute), Johany Peñailillo(Brigham and Women's Hospital), J. Bryan Iorgulescu(Broad Institute), Yeonjoo Hwang(UCSF Helen Diller Family Comprehensive Cancer Center), Christine E. Ryan(Dana-Farber Cancer Institute), Denise P. Muñoz(University of California, San Francisco), Shazib Pervaiz(National University of Singapore), Constantine S. Mitsiades(Dana-Farber Cancer Institute), Yaw Chyn Lim(National University of Singapore), Richard R. Furman(Cornell University)
Cited by 43
Related Papers
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
|Unknown|2008|4.1k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k